FDA warns about risk of atypical femoral fractures associated with bisphosphonate use

The FDA on Wednesday warned health care providers and patients about an increased risk of atypical femoral fracture in patients treated with bisphosphonates to prevent or treat osteoporosis. The agency said that the labels of the drugs would be changed and a medication guide would be released to reflect this risk.

Reference Articles
FDA: Possible increased risk of thigh bone fracture with bisphosphonates - (FDA)
FDA warns of fractures with osteoporosis drugs - (MSN Money)
FDA warns of thigh fractures with bone drugs - (Yahoo!News)

**Published in "First Word"